RESPONSE

Claims 1-7 and 9-20 are withdrawn in the present application. Claim 8 is presently amended, support for which can be found at least at page 28, line 27 of the PCT application.

Claim 8 stands rejected under Section 103 as obvious over various combinations of references. Claim 8 has now been amended to provide that the heterologous protein to which the CPP protein is fused is an IgG Fc protein. None of the cited combinations of references teaches or suggests such a fusion protein. Withdrawal of the rejection is respectfully requested.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139

September 4, 2008

(617) 871-3343

Date

Paul J. Paglierani Attorney for Applicants Reg. No. 52,498